PRKCA and metabolic dysfunction-associated steatotic liver disease: In NAFLD, aberrant activation of PKCα by integrin β1 promotes hepatic lipid droplet accumulation, with knockout or inhibition of PKCα significantly attenuating the fatty liver phenotype [274].